The field of pharmacogenomics (or the identification of biomarkers regarding drug metabolism and activity to inform precision prescribing) is rapidly advancing for individuals with ASD, but these advances are not equitably benefiting all communities. Specifically, Black and African American families’ participation in pharmacogenomic studies is significantly lower than white families, which limits the clinical utility of the information gathered for racial/ethnic minorities. Clinical data also suggests that Black families may be less likely to have access to clinical precision medicine supports. This work will survey the parents of youth with ASD to gather both quantitative and qualitative data to identify modifiable barriers and facilitators that can increase access to pharmacogenomic testing, openness to research participation and the downstream benefits of this evolving science for Black individuals with ASD.

2022-04-01

2023-03-31